Trial Profile

A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms GFM-Chimio-Rev

Most Recent Events

23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
23 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jan 2015 to 1 Dec 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com